Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUSNYSE:ADCTOTCMKTS:NEVPFOTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.2N/AN/AADCTADC Therapeutics$1.36+0.4%$1.64$1.28▼$5.38$131.02M1.51625,678 shs348,329 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$39.37-4.2%$41.37$29.20▼$44.31$251.10B0.413.23 million shs2.99 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ADCTADC Therapeutics0.00%-14.51%-15.05%-32.25%-68.38%NEVPFAbliva AB (publ)0.00%0.00%0.00%-22.22%+180.00%RHHBYRoche-4.16%-7.65%-5.88%+12.68%+25.46%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AADCTADC Therapeutics2.3257 of 5 stars3.53.00.00.02.30.80.6NEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ARHHBYRocheN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AADCTADC Therapeutics 3.00Buy$7.75471.96% UpsideNEVPFAbliva AB (publ) 0.00N/AN/AN/ARHHBYRoche 2.50Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest RHHBY, NEVPF, ACUS, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.003/31/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025ADCTADC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight2/24/2025ADCTADC TherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $8.002/13/2025RHHBYRocheUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/12/2025RHHBYRocheMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight1/30/2025RHHBYRocheSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/6/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AADCTADC Therapeutics$70.72M1.85N/AN/A($1.93) per share-0.70NEVPFAbliva AB (publ)$10K1,128.43N/AN/A$0.02 per share1.40RHHBYRoche$68.73B3.65$3.07 per share12.82$5.81 per share6.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AADCTADC Therapeutics-$240.05M-$1.65N/AN/AN/A-300.00%N/A-61.33%5/5/2025 (Estimated)NEVPFAbliva AB (publ)-$9.01MN/A0.00∞N/AN/A-117.92%-102.44%N/ARHHBYRoche$9.40BN/A0.0013.122.18N/AN/AN/AN/ALatest RHHBY, NEVPF, ACUS, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024ADCTADC Therapeutics-$0.35-$0.29+$0.06-$0.29$19.01 million$19.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AADCTADC TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ARHHBYRoche$0.852.16%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AADCTADC TherapeuticsN/A4.924.68NEVPFAbliva AB (publ)N/A7.997.99RHHBYRoche0.861.260.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AADCTADC Therapeutics41.10%NEVPFAbliva AB (publ)N/ARHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ADCTADC Therapeutics4.10%NEVPFAbliva AB (publ)N/ARHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableADCTADC Therapeutics31096.69 million92.73 millionOptionableNEVPFAbliva AB (publ)8403.01 millionN/ANot OptionableRHHBYRoche103,6056.38 billionN/ANot OptionableRHHBY, NEVPF, ACUS, and ADCT HeadlinesRecent News About These CompaniesRoche stock falls following Ocrevus trial updateApril 2 at 9:34 PM | investing.comRoche says MUSETTE trial did not meet primary endpointApril 2 at 9:34 PM | markets.businessinsider.comWhy Is Pharma Giant Roche Stock Trading Lower On Wednesday?April 2 at 3:12 PM | benzinga.comGenentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple SclerosisApril 2 at 12:01 PM | businesswire.comRoche fails in bid to increase dose of MS drug OcrevusApril 2 at 11:48 AM | reuters.comRoche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosisApril 2 at 11:45 AM | globenewswire.comQuest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer ScreeningApril 2 at 7:06 AM | prnewswire.comSaratoga Research & Investment Management Trims Position in Roche Holding AG (OTCMKTS:RHHBY)April 1 at 5:52 AM | marketbeat.comShort Interest in Roche Holding AG (OTCMKTS:RHHBY) Decreases By 68.8%March 28, 2025 | marketbeat.comLarge pharma M&A deals stalling amid volatile policies, Reuters reportsMarch 27, 2025 | markets.businessinsider.comF. Hoffmann-La Roche Ltd: Roche Annual General Meeting 2025March 25, 2025 | finanznachrichten.deRoche Annual General Meeting 2025March 25, 2025 | globenewswire.comThe Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto IndustriesMarch 25, 2025 | zacks.comRoche abandons global diversity targets on concern over U.S. executive ordersMarch 19, 2025 | reuters.comOxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of CancerMarch 19, 2025 | globenewswire.comRoche (OTCMKTS:RHHBY) Sets New 1-Year High - Time to Buy?March 18, 2025 | marketbeat.comBig pharma fears drug price spikes in US-EU tariff spat, Reuters saysMarch 18, 2025 | markets.businessinsider.comRoche to present new data at MDA conference on EvrysdiMarch 17, 2025 | markets.businessinsider.comRoche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conferenceMarch 17, 2025 | finance.yahoo.comRoche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conferenceMarch 17, 2025 | globenewswire.comLineage Cell Therapeutics price target lowered to $3 from $4 at B. RileyMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRHHBY, NEVPF, ACUS, and ADCT Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.ADC Therapeutics NYSE:ADCT$1.36 +0.01 (+0.37%) Closing price 04/2/2025 03:58 PM EasternExtended Trading$1.34 -0.01 (-1.11%) As of 04/2/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Abliva AB (publ) OTCMKTS:NEVPF$0.03 0.00 (0.00%) As of 04/1/2025Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Roche OTCMKTS:RHHBY$39.37 -1.71 (-4.16%) As of 04/2/2025 04:00 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
